Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial clinical trials with a tubless lithotriptor.

S B Lipson1, L S Ross, L P Sonda

  • 1Department of Urology, Michael Reese Hospital and Medical Center, Chicago, Illinois.

The Journal of Urology
|January 1, 1990
PubMed
Summary

The new Medstone 1050 tubeless lithotriptor effectively fragments kidney stones in 90% of patients. This initial study found no significant complications, paving the way for further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refinement of detecting atrial fibrillation in stroke patients: results from the TRACK-AF Study.

European journal of neurology·2017
Same author

Computational models for detection of endocrinopathy in subfertile males.

International journal of impotence research·2007
Same author

The future of sexual medicine for the urologist.

International journal of impotence research·2006
Same author

Surgical sperm retrieval for assisted reproduction.

Minerva ginecologica·2004
Same author

Apoptosis in the developing zebrafish embryo.

Developmental biology·2002
Same author

The transporter-like protein inebriated mediates hyperosmotic stimuli through intracellular signaling.

The Journal of experimental biology·2000

Area of Science:

  • Urology
  • Medical Devices
  • Nephrology

Background:

  • Kidney stones (nephrolithiasis) are a common condition requiring effective treatment.
  • Existing lithotripsy methods may have limitations.
  • The Medstone 1050 is a novel tubeless lithotriptor developed for stone fragmentation.

Purpose of the Study:

  • To evaluate the safety and efficacy of the Medstone 1050 lithotriptor.
  • To present initial human treatment data for this new device.

Main Methods:

  • A human treatment protocol was developed under Food and Drug Administration guidelines.
  • Fifty patients with renal or proximal ureteral stones (≤3 cm) were treated.
  • Patients were followed for a minimum of 3 months post-treatment.

Main Results:

  • An adequate stone fragmentation rate of 90% was achieved.
  • No significant complications were observed in any of the treated patients.
  • The device is tubeless, potentially offering procedural advantages.

Conclusions:

  • The Medstone 1050 demonstrates high fragmentation rates and a favorable safety profile in initial patient treatments.
  • Further investigation in a larger, multicenter study is warranted to confirm these findings.

Related Experiment Videos